Genotype-dependent efficacy of a dual PI3K/mTOR inhibitor, NVP-BEZ235, and an mTOR inhibitor, RAD001, in endometrial carcinomas

MLA

Frank McCormick, et al. “Genotype-Dependent Efficacy of a Dual PI3K/MTOR Inhibitor, NVP-BEZ235, and an MTOR Inhibitor, RAD001, in Endometrial Carcinomas.” PLoS ONE, vol. 7, no. 5, Jan. 2012. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....bdb9afd0ac461b173d2a1331716da1ff&authtype=sso&custid=ns315887.

APA

Frank McCormick, Hiroyuki Kuramoto, Shunsuke Nakagawa, Takahiro Koso, Kenbun Sone, Tetsu Yano, Yoko Matsumoto, Shiro Kozuma, Kei Kawana, Haruko Hiraike, Yuji Ikeda, Tomoko Kashiyama, Michihiro Tanikawa, Yuichiro Miyamoto, Osamu Wada-Hiraike, Keiko Shoji, Yuji Taketani, Hiroyuki Aburatani, Aki Miyasaka, & Katsutoshi Oda. (2012). Genotype-dependent efficacy of a dual PI3K/mTOR inhibitor, NVP-BEZ235, and an mTOR inhibitor, RAD001, in endometrial carcinomas. PLoS ONE, 7(5).

Chicago

Frank McCormick, Hiroyuki Kuramoto, Shunsuke Nakagawa, Takahiro Koso, Kenbun Sone, Tetsu Yano, Yoko Matsumoto, et al. 2012. “Genotype-Dependent Efficacy of a Dual PI3K/MTOR Inhibitor, NVP-BEZ235, and an MTOR Inhibitor, RAD001, in Endometrial Carcinomas.” PLoS ONE 7 (5). http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....bdb9afd0ac461b173d2a1331716da1ff&authtype=sso&custid=ns315887.